×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kristie L. Kahl
Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.
Suzann B. Goldstein
What a force they were, those two daughters of ours: that little nine-year-old kid Valerie, gone from bone cancer and the more grown-up 37-year-old Stacy, cut off by breast cancer. When we talk of them, however, it is often with a slight grin.
Matthew Tontonoz
Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.
Katie Kosko
Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

 
Brielle Benyon
The Food and Drug Administration approved Keytruda for the treatment of patients with metastatic small cell lung cancer.
Kristie L. Kahl
Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.
Kristie L. Kahl
A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.
Karen Peterson
When my oncologist wanted to start me on a standard treatment, I asked her why. She said some of her other patients had gotten it. She was basing my life on someone else’s results? This survivor decided to seek other opinions and became her own advocate.
Katie Kosko
Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.
Kristie L. Kahl
While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other